BVF Inc. IL Has $50.29 Million Stock Position in Immunocore Holdings PLC Sponsored ADR $IMCR

BVF Inc. IL cut its stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 5.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,488,975 shares of the company’s stock after selling 85,313 shares during the period. Immunocore comprises approximately 1.7% of BVF Inc. IL’s holdings, making the stock its 21st largest holding. BVF Inc. IL owned approximately 2.95% of Immunocore worth $50,294,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of IMCR. Leonteq Securities AG acquired a new position in shares of Immunocore in the 4th quarter worth approximately $30,000. Harbour Investments Inc. raised its holdings in shares of Immunocore by 60.2% in the 4th quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock worth $36,000 after buying an additional 388 shares in the last quarter. Arax Advisory Partners raised its holdings in shares of Immunocore by 302.9% in the 4th quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock worth $48,000 after buying an additional 1,042 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Immunocore by 37.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock worth $74,000 after buying an additional 572 shares in the last quarter. Finally, Osaic Holdings Inc. raised its holdings in shares of Immunocore by 117.4% in the 2nd quarter. Osaic Holdings Inc. now owns 3,148 shares of the company’s stock worth $97,000 after buying an additional 1,700 shares in the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

IMCR has been the subject of a number of recent research reports. HC Wainwright reissued a “buy” rating and issued a $100.00 target price on shares of Immunocore in a report on Monday, April 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a report on Tuesday, April 21st. Jefferies Financial Group cut Immunocore from a “buy” rating to a “hold” rating and dropped their target price for the stock from $48.00 to $33.00 in a report on Monday, March 16th. Wall Street Zen upgraded Immunocore from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Needham & Company LLC increased their price target on Immunocore from $71.00 to $75.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $56.71.

Immunocore Stock Up 1.3%

NASDAQ IMCR opened at $28.55 on Thursday. The firm has a market cap of $1.45 billion, a PE ratio of -51.91 and a beta of 0.74. Immunocore Holdings PLC Sponsored ADR has a one year low of $27.56 and a one year high of $40.71. The stock’s 50 day simple moving average is $29.45 and its 200 day simple moving average is $32.04. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.18 and a quick ratio of 4.15.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.51. The business had revenue of $106.68 million for the quarter, compared to analyst estimates of $145.20 million. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.Immunocore’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.10 EPS. As a group, sell-side analysts forecast that Immunocore Holdings PLC Sponsored ADR will post 0.06 earnings per share for the current fiscal year.

Immunocore Profile

Immunocore plc is a clinical?stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T?cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T?cell receptors against cancer) platform utilizes engineered, soluble T?cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease?associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma?associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.